TACE术治疗的原发性肝癌患者血清IL-33水平变化及其对发热的鉴别意义探讨*

doi:10.3969/j.issn.1672-5069.2023.06.030

摘要/Abstract

摘要： 目的探讨血清白细胞介素-33(IL-33)预测经导管肝动脉化疗栓塞(TACE)术后发热的原发性肝癌(PLC)患者细菌感染的价值。方法 2020年4月～2022年4月我院收治的PLC患者150例,均接受TACE治疗,术后发热。采用标本培养和影像学检查,综合判断细菌感染。采用ELISA法检测血清IL-33水平,常规检测降钙素原(PCT)。应用SPSS统计学软件绘制受试者工作特征曲线(ROC),计算曲线下面积(AUC),判断血清IL-33和PCT水平预测PLC患者细菌感染的效能。结果在本组PLC患者中,TACE术后发生细菌感染者50例(33.3%);细菌感染组基线糖尿病合并率、肿瘤TNM Ⅲ期、肿瘤大于5 cm和肿瘤多发占比显著高于非细菌感染组(P<0.05);细菌感染患者血清PCT和IL-33水平分别为(14.91±3.23)ng/mL和(42.2±8.5)pg/mL,显著高于非细菌感染患者【分别为(0.06±0.01)pg/mL和(13.4±4.9)pg/mL,P<0.05】;以血清PCT、IL-33水平和两者联合诊断细菌感染的AUC分别为0.869(95%CI=0.804～0.898,P<0.001)、0.786(95%CI=0.712～0.849,P<0.001)和0.895(95%CI=0.855～0.912,P<0.001),以联合诊断效能最优,其敏感度为0.770,特异度为0.930。结论监测血清IL-33和PCT水平可帮助诊断TACE术后发热的PLC患者细菌感染,值得开展扩大验证研究。

关键词: 原发性肝癌, 经导管肝动脉化疗栓塞术, 细菌感染, 白介素-33, 降钙素原, 诊断

Abstract: Objective The purpose of this study was to explore the predictive efficacy of serum interleukin-33 (IL-33) and procalcitonin (PCT) levels for bacterial infection in primary liver cancer (PLC) patients with fever after transcatheter arterial chemoembolization (TACE). Methods A total of 150 patients with PLC were enrolled in our hospital between April 2020 and April 2022, and all patients underwent TACE. The bacterial infection was diagnosed based on blood routine, serology, imaging and bacterial characterization. Serum IL-33 level was detected by ELISA. The receiver operating characteristic (ROC) curves were drawn by SPSS statistical software and the diagnostic performance was analyzed by the area under the ROC curve (AUC). Results Out of the 150 patients with PLC, the bacterial infection was diagnosed in 50 cases(33.3%) after TACE; the incidence of diabetes, tumor in TNM Ⅲ stage, the diameters of tumor greater than 5 cm and the multiple tumors in patients with bacterial infection were much higher than in patients without (P<0.05); serum PCT and IL-33 levels in patients with bacterial infection were (14.91±3.23) ng/mL and (42.2±8.5)pg/mL, significantly higher than [(0.06±0.01)pg/mL and (13.4±4.9)pg/mL, respectively, P<0.05] in patients without; the AUCs were 0.869(95%CI=0.804-0.898, P<0.001), 0.786(95%CI=0.712-0.849, P<0.001) and 0.895(95%CI=0.855-0.912, P<0.001) when serum PCT, IL-33 levels and combination of the two parameters were applied to predict bacterial infection in PLC patients with fever after TACE, suggesting the combination superior to serum PCT or IL-33 alone (Z=1.784, P=0.074) as the combination having the sensitivity of 0.770 and the specificity of 0.930. Conclusion The increased serum IL-33 and PCT levels might hint the bacterial infection in PLC patients with fever after TACE, and warrants further clinical investigation.

Key words: Hepatoma, Transcatheter arterial chemoembolization, Bacterial infection, Interleukin-33, Procalcitonin, Diagnosis

莫春明, 黄德佳, 韦惠章, 罗江伟. TACE术治疗的原发性肝癌患者血清IL-33水平变化及其对发热的鉴别意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 887-890.

Mo Chunming, Huang Dejia, Wei Huizhang, et al. Predictive efficacy of serum IL-33 and procalcitonin levels for bacterial infection in primary liver cancer patients with fever after TACE[J]. Journal of Practical Hepatology, 2023, 26(6): 887-890.

参考文献

[1] Liu CY, Chen KF, Chen PJ. Treatment ofliver cancer. Cold Spring Harb Perspect Med, 2015,5(9):21535.
[2] Arslan M, Degirmencioglu S. Risk factors for postembolization syndrome after transcatheter arterial chemoembolization. Curr Med Imaging Rev, 2019,15(4):380-385.
[3] Piscaglia F, Tovoli F, Pini P, et al. A new horizon in the prevention of the postembolization syndrome after transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatology, 2018,67(2):467-469.
[4] Cayrol C, Girard JP. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunol Rev, 2018,281(1):154-168.
[5] Rostan O, Arshad MI, Piquet-Pellorce C, et al. Crucial and diverse role of theinterleukin-33/ST2 axis in infectious diseases. Infect Immun, 2015,83(5):1738-1748.
[6] 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版). 中华消化外科杂志,2017,16(7):635-647.
[7] 叶应妩, 王毓三. 全国临床检验操作规程(第二版). 南京: 东南大学出版社, 2006:736-883.
[8] Sia D, Villanueva A, Friedman SL, et al. Livercancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology, 2017,152(4):745-761.
[9] Shao Z, Liu X, Peng C, et al. Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: a review. World J Surg Oncol, 2021,19(1):293.
[10] Galanakis N, Kehagias E, Matthaiou N, et al. Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review. Hepat Oncol, 2018,5(2):7-10.
[11] 陈子德,陈晓明. 肝癌栓塞后综合征研究概况. 实用医学杂志,2014(21):3524-3527.
[12] Chao Y, Wu CY, Kuo CY, et al. Cytokines are associated with postembolization fever and survival in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization. Hepatol Int, 2013,7(3):883-892.
[13] Chang L, Wang W, Jiang N, et al. Dexamethasone prevents TACE-induced adverse events: A meta-analysis. Medicine (Baltimore), 2020,99(47):23191.
[14] Zhou L, Zhang LZ, Wang JY, et al. Perioperative safety analysis of transcatheter arterial chemoembolization for hepatocellular carcinoma patients with preprocedural leukopenia or thrombocytopenia. Mol Clin Oncol, 2017,7(3):435-442.
[15] Dabbous HK, Ali-Eldin FA, Montasser IM. Role of procalcitonin in diagnosis of bacterial infection in trans-arterial chemoembolisation treated hepatocellular carcinoma patients. Arab J Gastroenterol, 2015,16(1):10-13.
[16] 王燕玲,何丽,王燕燕,等. 晚期肝癌患者TACE术后医院感染病原菌与影响因素分析. 中华医院感染学杂志,2019,29(4):578-581.
[17] Hong J, Kim S, Lin PC. Interleukin-33 and ST2signaling in tumor microenvironment. J Interferon Cytokine Res, 2019,39(1):61-67.
[18] Faustino LD, Griffith JW, Rahimi RA, et al. Interleukin-33 activates regulatory T cells to suppress innate γδ T cell responses in the lung. Nat Immunol, 2020,21(11):1371-1383.
[19] 李晓君,李新丽,胡佳扬,等. 老年胃癌根治术后肺部感染IL-33和Th1/Th2表达及意义. 中华医院感染学杂志,2021,31(14):2189-2192.
[20] Zeng S, Wu J, Liu J, et al. IL-33receptor (ST2) signalling is important for regulation of th2-mediated airway inflammation in a murine model of acute respiratory syncytial virus infection. Scand J Immunol, 2015,81(6):494-501.
[21] Griesenauer B, Paczesny S. The ST2/IL-33axis in immune cells during inflammatory diseases. Front Immunol, 2017,8(1):475.
[22] Glineur C, Leleu I, Pied S. The IL-33/ST2pathway in cerebral malaria. Int J Mol Sci, 2022,23(21):13457.

TACE术治疗的原发性肝癌患者血清IL-33水平变化及其对发热的鉴别意义探讨^*

Predictive efficacy of serum IL-33 and procalcitonin levels for bacterial infection in primary liver cancer patients with fever after TACE

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邵孝如, 周筱, 葛颖颖. ¹⁸F-FDG摄取量诊断非酒精性脂肪性肝病患者罹患冠状动脉粥样硬化性心脏病探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 811-814.
[2]	丁晓洁, 张永明, 宋海燕, 王文平, 宋洁, 撒小军, 邹永红. 2型糖尿病合并非酒精性脂肪性肝病患者NLR和PLR变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 815-818.
[3]	阎道博, 朱海超, 闪海霞. 瞬时弹性成像联合APRI诊断自身免疫性肝炎患者肝纤维化效能研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 831-834.
[4]	田宇, 陈燕, 曹佳非, 周晓倩. 肝硬化并发肝肾综合征患者U-mAl及外周血NLR和血清NGAL水平变化研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 859-862.
[5]	刘欢, 陈鹏, 蒯文涛, 徐亮. 肝脏硬度测定、血小板计数/脾厚比值和脾静脉直径预测肝硬化并发食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 867-870.
[6]	贺梅年, 赵思佳, 田智超, 何秀英, 巴正武. 超声半定量评分结合弹性成像诊断慢性乙型肝炎患者早期肝硬化临床价值分析^*[J]. 实用肝脏病杂志, 2023, 26(6): 871-874.
[7]	刘公攀, 陈涛, 丁志刚, 任明, 郭兴军, 邵存华, 卢建树. CalliSpheres可载药微球经导管肝动脉化疗栓塞序贯射频消融治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 879-882.
[8]	刘思宏, 谢琉嘉, 周志明, 许亚春. CEUS联合MRI增强扫描早期评价射频消融治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 895-898.
[9]	楼鹏, 邓继红, 严铭一. 腹腔镜肝切除术治疗原发性肝癌患者应用右美托咪定复合布托啡诺术后镇痛效果研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 899-902.
[10]	周莉, 丁云清, 袁凤英, 陈竹, 冯志伟. 超声造影判断乙型肝炎肝硬化患者肝内占位性病变性质价值研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 903-906.
[11]	张蕊, 时倩倩, 王仲秋. DCE-MRI、DWI和MRCP联合诊断肝外胆管癌临床价值研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 923-926.
[12]	黄柏盛, 区蓝芯, 张莹洁, 方梦冰, 施梅姐, 黎胜, 萧焕明. FibroScan联合GPR、APRI和FIB-4诊断血清ALT正常的慢性HBV感染者肝纤维化价值分析^*[J]. 实用肝脏病杂志, 2023, 26(5): 618-621.
[13]	郝岸华, 杜忠彩, 周林, 马磊. 慢性乙型肝炎患者肝脏硬度检测和S指数变化及评估肝纤维化程度应用价值探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 630-633.
[14]	刘爱华, 符建, 陈小红. 瞬时超声弹性成像联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 634-637.
[15]	蔡欣, 辛春红, 牛洪凯, 兰春祥. 代谢相关脂肪性肝病患者血清HIF-1α、Chemerin和脂联素水平变化及临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 654-657.